Skip to main content

News & events

-

IBA and NorthStar Medical Radioisotopes Sign Contract for Rhodotron® Electron Beam Accelerator for Commercial Production of Therapeutic Radioisotope Actinium-225 (Ac-225)

Louvain-La-Neuve, Belgium, and BELOIT, Wis., USA November 18, 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and NorthStar Medical Radioisotopes, LLC, (‘NorthStar’) a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced a new contract in which NorthStar will purchase a third Rhodotron® TT300 HE electron beam accelerator from IBA.  The accelerator will be exclusively used for the production of no-carrier added (n.c.a.) actinium-225 (Ac-225), an important therapeutic radioisotope that is in highly limited supply and for which no commercial-scale production technology currently exists. NorthStar previously purchased two Rhodotron® accelerators from IBA for its newly completed molybdenum-99 (Mo-99) production facility. “We look forward to continuing to work with IBA, who have shown extensive commercial expertise and excellent performance in delivering electron beam accelerators for our Mo-99 production expansion project,” said Stephen Merrick, President and Chief Executive Officer of NorthStar. “NorthStar is at the forefront of U.S. radioisotope production as the only commercialized producer of the diagnostic imaging radioisotope molybdenum-99 (Mo-99). We are applying that same development expertise to rapidly advance large-scale availability of the therapeutic radioisotope Ac-225 for use in oncology and other indications, and we are excited about its potential in these disease areas.”    Olivier Legrain, Chief Executive Officer of IBA commented, “We are delighted to sign this latest contract with NorthStar Medical Radioisotopes and to continue to deliver innovative solutions for reliable radioisotope supply. IBA’s Rhodotron® accelerators provide the most advanced electron accelerator technology in the world, and we are excited for the opportunity to create new therapeutic radioisotopes such as Ac-225. With its radiotheranostic capabilities, combining targeted diagnosis and therapy, we believe that this radioisotope has significant potential in the treatment of cancer.”   The final stage of facility design is underway for NorthStar’s state-of-the-art Therapeutic Radioisotope production facility, which will be exclusively dedicated to Ac-225 production, with construction scheduled to begin in early 2022. Initial production of Ac-225 is planned for late 2023, and a Drug Master File will be submitted to the FDA in 2024. NorthStar’s proprietary process for the production of Ac-225 will use IBA’s Rhodotron® to enable commercial-scale n.c.a. Ac-225 production that is free of long-life radioactive by products associated with other production methods.    
See more
-

IBA BUSINESS UPDATE – THIRD QUARTER 2021

Louvain-La-Neuve, Belgium, November 18, 2021 –IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its business update for the third quarter ending 30 September 2021.   Group Overview Strong performance across all business lines Ongoing commitment to stakeholder approach, delivering the best offering to our customers and investing for long-term sustainable growth whilst meeting ESG targets Strong balance sheet maintained, with EUR 91 million unaudited net cash (30 June 2021: EUR 69 million) Olivier Legrain, Chief Executive Officer of IBA commented:“IBA has continued to perform strongly in the second half of 2021 with solid progress across all business units. We have a highly active pipeline of new opportunities and are particularly excited about the marked revival in proton therapy activity in the important US market. Our Other Accelerators and Dosimetry businesses have also been exceptionally strong in the second half of the year with encouraging momentum as we approach 2022. “A core component of our roadmap towards sustainable growth is investment in future innovation to deliver strategic impact. In this regard, we were pleased to provide updates on a range of initiatives at the recent ASTRO conference, as well as several strategic partnerships, including in the promising field of radiotherapeutics. We are very excited about future prospects across our business lines and are in a confident position to achieve long-term profitability, with our stakeholder approach underpinning all of our business activities.”   Business Unit Highlights (including post-period end)   Proton Therapy 13 Proteus®ONE[1] and 8 Proteus®PLUS1 projects currently ongoing. Strong pipeline of new global opportunities with significant activity in the US and Asia Contract signed for a five room Proteus®PLUS System in China including a multi-year service contract Post-period end, finalized contract with Advocate Radiation Oncology in Florida, which previously selected IBA’s Proteus®ONE for its new Radiation Oncology Centre, including a multi-year service contract Post-period end, announced updates at ASTRO, including expansion of strategic partnership with RaySearch within Flash and proton ARC therapy projects, and the launch of Campus, the world’s first online proton therapy platform   Other Accelerators (RadioPharma, Industrial) and Dosimetry Strong performance in Other Accelerators in the third quarter, with 23 machines sold in the year to date of which 11 machines were sold in Asia Strategic R&D partnership announced with SCK CEN to enable the production of Actinimum-225 (Ac-225), a novel therapeutic radioisotope which has significant potential in the treatment of cancer Post-period end, announced a strategic partnership with TRAD Tests & Radiations to enable the development of a new radiation processing module, addressing an increasing unmet need in the sterilization market Dosimetry revenues and order book have continued to strengthen, further demonstrating the success of the business unit’s recent product launches   Outlook During the third quarter of 2021, IBA’s performance has continued to accelerate with strong progress across all business lines. Our pipeline is very active, particularly in the US and in Asia, and, coupled with the robust balance sheet and predictable revenue base of the services business, provides encouraging visibility for the period ahead. Whilst we are confident about business performance, the ongoing complex situation with the pandemic means that we are still unable to provide reliable financial guidance. We will provide a further update at the time of the 2021 full year results in March 2022.   [1]*Proteus®ONE and Proteus®PLUS are brand names of Proteus 235
See more

Who we are

Based on 35 years of experience, IBA RadioPharma Solutions helps nuclear medicine department to design, build and operate PET centers for the production of radiopharmaceuticals used for the detection and treatment of cancer and other critical diseases.

IBA works with you and supports you right through the whole process, from our first meeting through design, setting-up and operation. More than that, your IBA expert will support you throughout the lifetime of your radiopharmacy with trainings, updates and maintenances, to ensure the success of your project, for a sustainable future.

Read more
Who we are

Key facts

<strong>30</strong> Ci (up to)

Per production run.

For FDG production.

<strong>3</strong> (up to)

In one hotcell.

Multi tracers. Multi runs.

<strong>650</strong> +

Synthera® radiosynthesis modules installed worldwide.

<strong>300</strong> +

Cyclotrons operating and supported on 5 continents.